Develops monoclonal antibodies for autoimmune diseases.
Dec 2025Revenue $2.04M/yrExpenses $180M/yr
No trendCash runway ≈ 5.7 years from Jun 2026
Figures by year
When will Dianthus Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $2.04M and expenses $180M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.04M | $180M | −$178M |
| Dec 2024 | $6.24M | $108M | −$102M |
| Dec 2023 | $2.83M | $51.0M | −$48.2M |
| Dec 2019 | $0.00 | $83.0M | −$83.0M |
| Dec 2018 | $0.00 | $60.0M | −$60.0M |
| Dec 2017 | $0.00 | $35.7M | −$35.7M |
| Dec 2016 | $0.00 | $9.27M | −$9.27M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.